Early study of a new catheter valve for tricuspid regurgitation
Part of Heart & circulation clinical trials.
This trial tests a new “through-the-vein” (catheter) valve procedure to treat leaky tricuspid valve (tricuspid regurgitation) in people who still have symptoms despite best medical therapy. If you qualify, it may help improve valve function and symptoms, while doctors closely track safety and follow-up results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your heart team thinks your tricuspid valve leak is causing symptoms even with medicines (including water pills/diuretics), and you’re a candidate for a bioprosthetic valve replacement
- Your heart team says you have an intermediate (or higher) risk of death with tricuspid valve surgery
- Your echo tests (ultrasound) show severe tricuspid regurgitation, based on specialist review
- You’re at least NYHA class II (symptoms with activity) and can be treated through a vein from the groin using the trial device
- You and your doctor agree you can return for all required follow-up visits after the procedure
- You have enough life expectancy (24 months or more) to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study tests a new, less invasive way to replace the tricuspid valve (the valve between the right upper and lower heart chambers) in people with severe leakage. The valve is delivered through a vein in the neck or leg, avoiding open-heart surgery.
This trial tests a new device called Laplace TTVR to replace a leaky tricuspid valve in the heart without open surgery. It is for people with severe symptoms despite medical treatment.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This study tests a new catheter-based device to repair a leaky tricuspid heart valve (tricuspid regurgitation) in people who still have symptoms like shortness of breath or swelling despite taking heart medications. The goal is to see if the procedure is safe and can help reduce the leak.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.